Knight Jeff E. — SEC Form 4 filings
SEC reporting owner CIK 1881007. 12 Form 4 filings on record with FilingPulse; latest filed 2026-04-17.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-03-06 to 2026-04-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 7 filings — 163,052 shares, $7,019,830 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: sale of 85,163 shares @ $40.10 ($3,415,036) in Crinetics Pharmaceuticals, Inc., filed 2026-04-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. (CRNX) | Chief Dev. & Operating Officer | 11 | — | 10 legs · 163,052 sh · $7,019,830 | 21 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | Chief Dev & Operating Officer | 1 | — | — | 1 |
Form 4 filings — Knight Jeff E.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-04-17 | 4 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2026-04-10 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Option exercise (M): 49,474 @ $23.98 · Option exercise (M): 9,624 @ $20.02 · Option exercise (M): 19,336 @ $19.64 · Sale (S): 85,163 @ $40.10 · Option exercise (M): 49,474 (derivative) @ $0 · Option exercise (M): 9,624 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-18 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Sale (S): 5,950 @ $37.11 · Sale (S): 3,961 @ $37.77 | EDGAR |
| 2026-02-25 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 34,000 @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Sale (S): 6,801 @ $34.17 · Sale (S): 361 @ $34.83 | EDGAR |
| 2025-02-24 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 43,000 @ $0 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-11-26 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Sale (S): 501 @ $56.52 | EDGAR |
| 2024-07-17 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Option exercise (M): 17,499 @ $23.98 · Option exercise (M): 2,887 @ $20.02 · Option exercise (M): 5,687 @ $19.64 · Sale (S): 27,000 @ $55 · Option exercise (M): 17,499 (derivative) @ $0 · Option exercise (M): 2,887 (derivative) @ $0 · +1 more | EDGAR |
| 2024-06-28 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Sale (S): 956 @ $44.38 | EDGAR |
| 2024-03-26 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Option exercise (M): 30,000 @ $23.98 · Sale (S): 30,000 @ $44.22 · Sale (S): 2,359 @ $45.39 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2024-03-20 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Tax withholding (F): 4,283 @ $38.14 | EDGAR |
| 2024-03-06 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 23,000 @ $0 · Grant/award (A): 87,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1881007 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →